Louisiana State Employees Retirement System Sells 800 Shares of Eli Lilly and Company (NYSE:LLY)

Louisiana State Employees Retirement System decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.8% in the third quarter, Holdings Channel reports. The firm owned 44,400 shares of the company’s stock after selling 800 shares during the quarter. Eli Lilly and Company accounts for about 0.7% of Louisiana State Employees Retirement System’s portfolio, making the stock its 13th biggest position. Louisiana State Employees Retirement System’s holdings in Eli Lilly and Company were worth $39,336,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Outlook Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 35.4% in the 3rd quarter. Outlook Wealth Advisors LLC now owns 306 shares of the company’s stock worth $271,000 after purchasing an additional 80 shares in the last quarter. Convergence Financial LLC increased its holdings in shares of Eli Lilly and Company by 9.1% in the 3rd quarter. Convergence Financial LLC now owns 3,596 shares of the company’s stock worth $3,186,000 after purchasing an additional 299 shares in the last quarter. Sigma Investment Counselors Inc. increased its holdings in shares of Eli Lilly and Company by 9.5% in the 3rd quarter. Sigma Investment Counselors Inc. now owns 1,341 shares of the company’s stock worth $1,188,000 after purchasing an additional 116 shares in the last quarter. Massachusetts Wealth Management grew its holdings in shares of Eli Lilly and Company by 15.6% in the third quarter. Massachusetts Wealth Management now owns 2,560 shares of the company’s stock worth $2,268,000 after acquiring an additional 345 shares during the period. Finally, Lake Street Advisors Group LLC grew its holdings in shares of Eli Lilly and Company by 0.7% in the third quarter. Lake Street Advisors Group LLC now owns 10,808 shares of the company’s stock worth $9,575,000 after acquiring an additional 72 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.2 %

Shares of NYSE LLY opened at $892.70 on Friday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The business’s 50 day moving average price is $919.74 and its 200-day moving average price is $862.48. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53. The company has a market cap of $848.45 billion, a price-to-earnings ratio of 109.94, a PEG ratio of 3.24 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, sell-side analysts expect that Eli Lilly and Company will post 14.05 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Citigroup lifted their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.